Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2026 08:00 ET | Source: Neurona Therapeutics

Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX-1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting

- UNILATERAL MTLE: Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy evaluation period (N=9), and 100% median disabling...
April 21, 2026 16:30 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in...
April 01, 2026 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...
February 24, 2026 16:05 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics to Participate in Upcoming Investor Conferences
January 06, 2026 07:16 ET | Source: Bright Minds Biosciences

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3%...
December 18, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 08, 2025 08:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society

Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society
December 05, 2025 09:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’...
November 18, 2025 16:05 ET | Source: Neurona Therapeutics

Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer

SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system,...
November 05, 2025 16:05 ET | Source: Neurona Therapeutics

Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy

SAN FRANCISCO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today...